Stock 688338 BEIJING SUCCEEDER TECHNOLOGY INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Beijing Succeeder Technology Inc.

Equities

688338

CNE1000044C4

Medical Equipment, Supplies & Distribution

End-of-day quote Shanghai S.E.
Other stock markets
 03:30:00 03/07/2024 am IST 		5-day change 1st Jan Change
21.97 CNY -1.39% Intraday chart for Beijing Succeeder Technology Inc. +1.34% -34.61%
28/06 Beijing Succeeder Technology Inc. announces an Equity Buyback for CNY 100 million worth of its shares. CI
26/06 Beijing Succeeder Technology Inc. authorizes a Buyback Plan. CI

Valuation

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Capitalization 1 3,644 2,694 3,566 2,332 - -
Enterprise Value (EV) 1 3,644 2,694 3,566 2,332 2,332 2,332
P/E ratio 37.5 x 25.8 x 30.8 x 16.6 x 13.7 x 11.3 x
Yield - 0.79% 0.77% 1.23% 1.5% 1.82%
Capitalization / Revenue - - 12.9 x 6.78 x 5.41 x 4.31 x
EV / Revenue - - 12.9 x 6.78 x 5.41 x 4.31 x
EV / EBITDA - - - - - -
EV / FCF - - - - - -
FCF Yield - - - - - -
Price to Book - 1.79 x 2.23 x 1.36 x 1.26 x 1.15 x
Nbr of stocks (in thousands) 1,06,143 1,06,143 1,06,142 1,06,142 - -
Reference price 2 34.33 25.38 33.60 21.97 21.97 21.97
Announcement Date 18/02/22 09/02/23 15/01/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Net sales 1 - - 276.2 344 431 541
EBITDA - - - - - -
EBIT 1 - 117.9 133.8 160 194 235
Operating Margin - - 48.46% 46.51% 45.01% 43.44%
Earnings before Tax (EBT) 1 - 119.9 133.8 162 196 237
Net income 1 97.37 104.1 116 140.5 170.1 206
Net margin - - 42.01% 40.85% 39.47% 38.07%
EPS 2 0.9154 0.9846 1.090 1.320 1.600 1.940
Free Cash Flow - - - - - -
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share 2 - 0.2000 0.2600 0.2700 0.3300 0.4000
Announcement Date 18/02/22 09/02/23 15/01/24 - - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Net Debt - - - - - -
Net Cash position - - - - - -
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow - - - - - -
ROE (net income / shareholders' equity) - 7.13% 7.48% 8.2% 9.17% 10.2%
ROA (Net income/ Total Assets) - - 6.93% 7.7% 8.5% 9.3%
Assets 1 - - 1,673 1,825 2,001 2,215
Book Value Per Share 2 - 14.20 15.10 16.10 17.50 19.10
Cash Flow per Share 2 - 0.9500 1.030 1.020 1.540 1.930
Capex 1 - 97.2 120 20 20 20
Capex / Sales - - 43.53% 5.81% 4.64% 3.7%
Announcement Date 18/02/22 09/02/23 15/01/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Beijing Succeeder Technology Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
21.97
Average target price
-
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

1st Jan change Capi.
BEIJING SUCCEEDER TECHNOLOGY INC. Stock Beijing Succeeder Technology Inc.
-34.61% 32Cr
BIOMÉRIEUX Stock bioMérieux
-7.80% 1.15TCr
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD. Stock Shenzhen New Industries Biomedical Engineering Co., Ltd.
-20.75% 669.84Cr
DIASORIN S.P.A. Stock DiaSorin S.p.A.
+7.21% 566.01Cr
LANTHEUS HOLDINGS, INC. Stock Lantheus Holdings, Inc.
+28.32% 551.45Cr
AUTOBIO DIAGNOSTICS CO., LTD. Stock Autobio Diagnostics Co., Ltd.
-21.94% 355.69Cr
ANDON HEALTH CO., LTD. Stock Andon Health Co., Ltd.
+6.32% 255.09Cr
10X GENOMICS, INC. Stock 10x Genomics, Inc.
-66.49% 224.45Cr
MYRIAD GENETICS, INC. Stock Myriad Genetics, Inc.
+30.36% 225.82Cr
VITROLIFE AB Stock Vitrolife AB
-11.81% 220.64Cr
Diagnostic & Testing Substances
  1. Stock Market
  2. Equities
  3. 688338 Stock
  4. Financials Beijing Succeeder Technology Inc.